FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175864573> ?p ?o ?g. }

• W3175864573 endingPage "2587" @default.
• W3175864573 startingPage "2573" @default.
• W3175864573 abstract "Patients with non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD) with poor performance status (PS) are common in clinical practice with few related studies. Present studies have found that weekly low-dose docetaxel or gemcitabine combined with platinum is suitable for elderly or poor PS patients with advanced NSCLC.Untreated advanced driver mutation-negative NSCLC patients with COPD and PS ≥2 were enrolled in this double-blind randomized trial. Both groups controlled their COPD symptoms according to the GOLD guidelines. The anti-tumor regimens included docetaxel (37.5 mg/m2, D1, D8)/carboplatin (AUC 5.0) (DC group) and gemcitabine (1,000 mg/m2, D1, D8)/carboplatin (AUC 5.0) (GC group) were used every 3 weeks with continuous chemotherapy for 4-6 cycles or until disease progression. The primary endpoints were progression-free survival (PFS), and overall survival (OS).Among the 52 patients (DC, n=25; GC, n=27), the median follow-up time was 12.3 months. There was no significant difference in tumor overall response rate (ORR; DC, 20.0% vs. GC, 22.2%, P=0.845) and disease control rate (DCR; DC, 72.0% vs. GC, 74.1%, P=0.064) between the 2 groups. The median PFS (GC, 6.5 vs. DC, 5.5 months; P=0.296) and the median OS (GC, 14.9 vs. DC, 12.3 months; P=0.548) of the GC group was slightly longer than the DC group. The main adverse reactions were myelosuppression and there were few adverse reactions of grade 3-4. Compared with the anti-tumor therapy only group in previous literature, the median PFS in this study was longer (6.2 months, 95% CI: 3.533-6.733 vs. 3.5 months, 95% CI: 2.432-4.568; P=0.589). There was also no significant difference in median OS and median PFS between the 2 groups (14.0 vs. 15.0 months, P=0.718). Chemotherapy cycle (P<0.001) was an independent prognostic factor for PFS, while chemotherapy cycle (P=0.011) and PS (P=0.041) were independent prognostic factors for OS.Weekly low-dose docetaxel or gemcitabine combined with carboplatin chemotherapy regimens can yield survival benefits and a tolerable safety profile in patients with driver mutation-negative advanced NSCLC and poor PS complicated with COPD, with no significant difference between the two regimens.Chinese Clinical Trial Registry ChiCTR-IPR-15006164." @default.
• W3175864573 created "2021-07-05" @default.
• W3175864573 creator A5009330947 @default.
• W3175864573 creator A5011207378 @default.
• W3175864573 creator A5014341292 @default.
• W3175864573 creator A5018024575 @default.
• W3175864573 creator A5033704922 @default.
• W3175864573 creator A5040558103 @default.
• W3175864573 creator A5041179186 @default.
• W3175864573 creator A5042111257 @default.
• W3175864573 creator A5048339590 @default.
• W3175864573 creator A5049965913 @default.
• W3175864573 creator A5050086429 @default.
• W3175864573 creator A5057313515 @default.
• W3175864573 creator A5071806695 @default.
• W3175864573 date "2021-06-01" @default.
• W3175864573 modified "2023-10-17" @default.
• W3175864573 title "Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease" @default.
• W3175864573 cites W1666120628 @default.
• W3175864573 cites W1757407923 @default.
• W3175864573 cites W1898736255 @default.
• W3175864573 cites W1899687218 @default.
• W3175864573 cites W1978225954 @default.
• W3175864573 cites W2031201020 @default.
• W3175864573 cites W2037139573 @default.
• W3175864573 cites W2040102762 @default.
• W3175864573 cites W2052606157 @default.
• W3175864573 cites W2058049114 @default.
• W3175864573 cites W2097268198 @default.
• W3175864573 cites W2099556905 @default.
• W3175864573 cites W2116141140 @default.
• W3175864573 cites W2119766544 @default.
• W3175864573 cites W2140005531 @default.
• W3175864573 cites W2140881907 @default.
• W3175864573 cites W2144765929 @default.
• W3175864573 cites W2147075384 @default.
• W3175864573 cites W2147675681 @default.
• W3175864573 cites W2149994797 @default.
• W3175864573 cites W2158077876 @default.
• W3175864573 cites W2160131381 @default.
• W3175864573 cites W2162149445 @default.
• W3175864573 cites W2163223439 @default.
• W3175864573 cites W2169237347 @default.
• W3175864573 cites W2228221433 @default.
• W3175864573 cites W2279412754 @default.
• W3175864573 cites W2360996316 @default.
• W3175864573 cites W2464859617 @default.
• W3175864573 cites W2602831557 @default.
• W3175864573 cites W2773289117 @default.
• W3175864573 cites W2773332949 @default.
• W3175864573 cites W2810038734 @default.
• W3175864573 cites W2872942565 @default.
• W3175864573 cites W2899466347 @default.
• W3175864573 cites W2901764801 @default.
• W3175864573 cites W2920797638 @default.
• W3175864573 cites W2943738181 @default.
• W3175864573 cites W2964471257 @default.
• W3175864573 cites W2995566311 @default.
• W3175864573 cites W3030529439 @default.
• W3175864573 cites W4249713788 @default.
• W3175864573 doi "https://doi.org/10.21037/tlcr-21-371" @default.
• W3175864573 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8264331" @default.
• W3175864573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34295663" @default.
• W3175864573 hasPublicationYear "2021" @default.
• W3175864573 type Work @default.
• W3175864573 sameAs 3175864573 @default.
• W3175864573 citedByCount "2" @default.
• W3175864573 countsByYear W31758645732023 @default.
• W3175864573 crossrefType "journal-article" @default.
• W3175864573 hasAuthorship W3175864573A5009330947 @default.
• W3175864573 hasAuthorship W3175864573A5011207378 @default.
• W3175864573 hasAuthorship W3175864573A5014341292 @default.
• W3175864573 hasAuthorship W3175864573A5018024575 @default.
• W3175864573 hasAuthorship W3175864573A5033704922 @default.
• W3175864573 hasAuthorship W3175864573A5040558103 @default.
• W3175864573 hasAuthorship W3175864573A5041179186 @default.
• W3175864573 hasAuthorship W3175864573A5042111257 @default.
• W3175864573 hasAuthorship W3175864573A5048339590 @default.
• W3175864573 hasAuthorship W3175864573A5049965913 @default.
• W3175864573 hasAuthorship W3175864573A5050086429 @default.
• W3175864573 hasAuthorship W3175864573A5057313515 @default.
• W3175864573 hasAuthorship W3175864573A5071806695 @default.
• W3175864573 hasBestOaLocation W31758645731 @default.
• W3175864573 hasConcept C126322002 @default.
• W3175864573 hasConcept C143998085 @default.
• W3175864573 hasConcept C168563851 @default.
• W3175864573 hasConcept C197934379 @default.
• W3175864573 hasConcept C203092338 @default.
• W3175864573 hasConcept C2776256026 @default.
• W3175864573 hasConcept C2776694085 @default.
• W3175864573 hasConcept C2776780178 @default.
• W3175864573 hasConcept C2778239845 @default.
• W3175864573 hasConcept C2780258809 @default.
• W3175864573 hasConcept C2781190966 @default.
• W3175864573 hasConcept C2781451048 @default.
• W3175864573 hasConcept C71924100 @default.
• W3175864573 hasConcept C90924648 @default.
• W3175864573 hasConceptScore W3175864573C126322002 @default.

• next